登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由中国科学技术大学附属第一医院(安徽省立医院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07188103,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
a. Patients with histologically confirmed esophageal squamous cell carcinoma (ESCC) , aged 18-80 years;
入选标准第 1 条
b. Unresectable locally advanced, postoperative recurrent, or metastatic ESCC that has progressed on or is intolerant to first-line systemic therapy. For patients who received definitive concurrent chemoradiotherapy (CCRT) , disease progression during or within 6 months post-treatment is considered first-line treatment failure;
入选标准第 2 条
e. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2;
入选标准第 15 条
Hemoglobin (Hb) ≥ 90 g/L
入选标准第 6 条
White blood cell (WBC) count ≥ 1.5 × 10⁹/L
入选标准第 7 条
Platelet count ≥ 60 × 10⁹/L
入选标准第 8 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN)
入选标准第 11 条
Total bilirubin ≤ 1.5 × ULN
入选标准第 12 条
Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 60 mL/min
入选标准第 13 条
c. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) . All positive regional lymph nodes are counted as a single lesion, while non-regional metastatic lymph nodes are counted per station;
入选标准第 3 条
h. Pregnant or lactating women;
排除标准第 8 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07188103,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
a. Patients with histologically confirmed esophageal squamous cell carcinoma (ESCC) , aged 18-80 years; b. Unresectable locally advanced, postoperative recurrent, or metastatic ESCC that has progressed on or is intolerant to first-line systemic therapy. For patients who received definitive concurrent chemoradiotherapy (CCRT) , disease progression during or within 6 months post-treatment is considered first-line treatment failure; c. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) . All positive regional lymph nodes are counted as a single lesion, while non-regional metastatic lymph nodes are counted per station; d. Adequate major organ function, defined as: Hematology: Hemoglobin (Hb) ≥ 90 g/L White blood cell (WBC) count ≥ 1.5 × 10⁹/L Platelet count ≥ 60 × 10⁹/L Serum biochemistry: Albumin ≥ 25 g/L Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN) Total bilirubin ≤ 1.5 × ULN Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 60 mL/min Echocardiography: e. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2; f. Expected survival ≥ 3 months; g. Voluntarily enrolled, with signed informed consent, and willing to comply with study protocols and follow-up.排除标准:Exclusion Criteria:
a. Patients with severe organ dysfunction, uncontrolled acute infection, or significant comorbidities; b. Patients with vertebral metastases accompanied by spinal cord compression symptoms; c. Patients with esophagotracheal or esophagomediastinal fistulas; d. Patients with uncontrolled pleural, pericardial, or pelvic effusions requiring repeated drainage; e. Patients with esophageal primary/metastatic lesions invading the heart or great vessels, as assessed by the responsible physician, with a risk of life-threatening hemorrhage; f. Patients with esophageal primary/metastatic lesions invading the trachea or bronchi, as assessed by the responsible physician, with a risk of esophagotracheal fistula; g. Patients not suitable for short-course hypofractionated radiotherapy, as evaluated by the responsible physician; h. Pregnant or lactating women; i. Patients with mental disorders, or those with a history of psychotropic drug abuse and unable to quit; j. Patients who have participated in other drug clinical trials within the past 4 weeks; k. Patients or their families who refuse to participate in the study.
引自 ClinicalTrials.gov, NCT07188103, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07188103,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。